Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,031,604
  • Shares Outstanding, K 607,222
  • Annual Sales, $ 2,289 M
  • Annual Income, $ 619,730 K
  • 60-Month Beta 0.34
  • Price/Sales 11.40
  • Price/Cash Flow 14.42
  • Price/Book 2.51
Trade RPRX with:

Options Overview Details

View History
  • Implied Volatility 21.67% ( +4.79%)
  • Historical Volatility 17.91%
  • IV Percentile 33%
  • IV Rank 41.47%
  • IV High 49.56% on 03/09/22
  • IV Low 1.91% on 08/29/22
  • Put/Call Vol Ratio 41.89
  • Today's Volume 815
  • Volume Avg (30-Day) 559
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 27,969
  • Open Int (30-Day) 23,931

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 1.54
  • Number of Estimates 3
  • High Estimate 1.61
  • Low Estimate 1.45
  • Prior Year 0.80
  • Growth Rate Est. (year over year) +92.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.41 +3.53%
on 11/03/22
44.01 -2.59%
on 11/10/22
+0.11 (+0.26%)
since 10/28/22
3-Month
39.60 +8.26%
on 09/26/22
44.19 -3.00%
on 09/12/22
-0.18 (-0.42%)
since 08/26/22
52-Week
36.15 +18.59%
on 02/24/22
44.75 -4.20%
on 04/14/22
+0.98 (+2.34%)
since 11/26/21

Most Recent Stories

More News
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Sector ETF report for IHE

IHE : 184.80 (+0.25%)
JNJ : 176.46 (-0.49%)
PFE : 49.61 (+0.08%)
RPRX : 42.98 (+0.26%)
PJP : 78.05 (-0.69%)
PPH : 75.89 (-0.08%)
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million...

ARWR : 30.14 (+7.64%)
RPRX : 42.98 (+0.26%)
Royalty Pharma (RPRX) Surpasses Q3 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.82% and 3.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

RPRX : 42.98 (+0.26%)
PX : 10.25 (-1.35%)
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%...

RPRX : 42.98 (+0.26%)
TBPH : 10.40 (-0.86%)
Why Earnings Season Could Be Great for Royalty Pharma (RPRX)

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

RPRX : 42.98 (+0.26%)
Phillips Edison & Company, Inc. (PECO) Q3 FFO and Revenues Top Estimates

Phillips Edison & Company, Inc. (PECO) delivered FFO and revenue surprises of 9.43% and 2.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

PECO : 31.47 (+0.45%)
RPRX : 42.98 (+0.26%)
Earnings Preview: Jackson Financial (JXN) Q3 Earnings Expected to Decline

Jackson Financial (JXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JXN : 37.71 (+1.10%)
RPRX : 42.98 (+0.26%)
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

There may be more trouble on the horizon for these stocks than most investors are seeing right now.

DE : 441.10 (-0.02%)
RPRX : 42.98 (+0.26%)
ERIE : 264.30 (-1.69%)
Do Warren Buffett's Recent Moves Spell Doom for This Group of Stocks?

The Oracle of Omaha doesn't like pharma stocks for some reason.

ORCL : 81.28 (-0.14%)
BRK.A : 471,738.47 (-0.21%)
BRK.B : 312.51 (-0.24%)
BRK-A : N/A (unch)
BRK-B : N/A (unch)
RPRX : 42.98 (+0.26%)
ABBV : 158.74 (+0.20%)
BMY : 78.92 (-0.28%)
PFE : 49.61 (+0.08%)
MRK : 108.24 (-0.19%)
JNJ : 176.46 (-0.49%)
Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up

Minerva's (NERV) stock surges after the company files an NDA-seeking FDA approval for its schizophrenia therapy.

JNJ : 176.46 (-0.49%)
RPRX : 42.98 (+0.26%)
NERV : 3.15 (-5.12%)
AERI : 15.25 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 43.55
2nd Resistance Point 43.32
1st Resistance Point 43.09
Last Price 42.98
1st Support Level 42.63
2nd Support Level 42.40
3rd Support Level 42.17

See More

52-Week High 44.75
Last Price 42.98
Fibonacci 61.8% 41.46
Fibonacci 50% 40.45
Fibonacci 38.2% 39.44
52-Week Low 36.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar